Microtubule inhibitors, such as taxanes, represent one of the most widely used treatments for cancer. By perturbing the mitotic spindle, taxanes activate the spindle assembly checkpoint (SAC), which subsequently induces mitotic arrest and cell death. However, cancers vary widely in their sensitivity to taxanes, perhaps due to differences in the strength of the checkpoint and efficiency of mitotic arrest. Because the only known function of the SAC is to inhibit the ubiquitin ligase activity of the Anaphase-Promoting Complex/Cyclosome (APC), direct APC inhibitors might be more effective at inducing mitotic arrest, without toxicities associated with microtubule perturbation. Using phenotypic screens in Xenopus cell cycle extracts, combined with biochemical studies to identify targets of active molecules, we have identified two small molecules that inhibit APC dependent proteolysis. This grant application encompasses four major goals. First, to understand, at the atomic level, how TAME and cyclinal interact with their protein targets. Second, to understand the detailed mechanisms by which these compounds perturb APC activity. Third, to understand how these compounds perturb regulation of APC by the SAC. Fourth, to leverage our understanding of the cellular effects of these molecules to identify new classes of APC inhibitors. Through our studies, we hope to establish a definitive mechanistic understanding of how these compounds inhibit APC activity and lay the intellectual and technical groundwork for development of APC inhibitors as drugs to treat cancer.
Microtubule inhibitors, such as taxanes, represent one of the most widely used treatments for cancer, but the responsiveness of different tumors can vary widely. Here we explore a new approach to treating cancer, by directly targeting proteins required for cell division. These compounds can arrest cells in mitosis and induce cell death more effectively than taxanes, providing a new approach for the treatment of cancer.
|Sackton, Katharine L; Dimova, Nevena; Zeng, Xing et al. (2014) Synergistic blockade of mitotic exit by two chemical inhibitors of the APC/C. Nature 514:646-9|
|Pfaff, Kathleen L; King, Randall W (2013) Determinants of human cyclin B1 association with mitotic chromosomes. PLoS One 8:e59169|
|Lim, Hui-Jun; Dimova, Nevena V; Tan, Meng-Kwang Marcus et al. (2013) The G2/M regulator histone demethylase PHF8 is targeted for degradation by the anaphase-promoting complex containing CDC20. Mol Cell Biol 33:4166-80|
|Krajcovic, Matej; Johnson, Nicole B; Sun, Qiang et al. (2011) A non-genetic route to aneuploidy in human cancers. Nat Cell Biol 13:324-30|
|Sigoillot, Frederic D; King, Randall W (2011) Vigilance and validation: Keys to success in RNAi screening. ACS Chem Biol 6:47-60|
|Bentley, Anna M; Normand, Guillaume; Hoyt, Jonathan et al. (2007) Distinct sequence elements of cyclin B1 promote localization to chromatin, centrosomes, and kinetochores during mitosis. Mol Biol Cell 18:4847-58|
|Hanna, John; Hathaway, Nathaniel A; Tone, Yoshiko et al. (2006) Deubiquitinating enzyme Ubp6 functions noncatalytically to delay proteasomal degradation. Cell 127:99-111|
|Kirkpatrick, Donald S; Hathaway, Nathaniel A; Hanna, John et al. (2006) Quantitative analysis of in vitro ubiquitinated cyclin B1 reveals complex chain topology. Nat Cell Biol 8:700-10|
|Crosas, Bernat; Hanna, John; Kirkpatrick, Donald S et al. (2006) Ubiquitin chains are remodeled at the proteasome by opposing ubiquitin ligase and deubiquitinating activities. Cell 127:1401-13|
|Salic, Adrian; King, Randall W (2005) Identifying small molecule inhibitors of the ubiquitin-proteasome pathway in Xenopus egg extracts. Methods Enzymol 399:567-85|
Showing the most recent 10 out of 14 publications